National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

razoxane
An orally bioavailable bis-dioxopiperazine and a derivative of the chelating agent ethylenediaminetetraacetic acid (EDTA) with antineoplastic, antiangiogenic, and antimetastatic activities. Razoxane specifically inhibits the enzyme topoisomerase II without inducing DNA strand breaks, which may result in the inhibition of DNA synthesis and cell division in the premitotic and early mitotic phases of the cell cycle. This agent may also exhibit antiangiogenic and antimetastatic activities although the precise molecular mechanisms of these actions are unknown. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Foreign brand name:Razoxin
Code names:ICI 59118
ICRF-159



Previous:Rapamune, ras peptide cancer vaccine, rasburicase, ravuconazole, RayGel
Next:Re-186 hydroxyethylidene diphosphonate, Rebetol, Rebif, rebimastat, Recentin

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov